Kanokrat RungtivasuwanAnchalee AvihingsanonNarukjaporn ThammajarukSiwaporn MitrukDavid M. BurgerKiat RuxrungthamChonlaphat SukasemBaralee PunyawudhoFaculty of Medicine, Ramathibodi Hospital, Mahidol UniversityThe HIV Netherlands Australia Thailand Research CollaborationChulalongkorn UniversityVajira HospitalRadboud University Nijmegen Medical CentreMahidol UniversityChiang Mai University2018-12-212019-03-142018-12-212019-03-142017-11-01Pharmacogenomics. Vol.18, No.16 (2017), 1481-149017448042146224162-s2.0-85034419484https://repository.li.mahidol.ac.th/handle/20.500.14594/41724© 2017 Future Medicine Ltd. Aim: To develop a population pharmacokinetic model and identify sources of variability, genetic and nongenetic factors, of tenofovir. Methods: The ABCC2 and ABCC4 polymorphisms were genotyped in 342 patients. A nonlinear mixed effects model was used to develop the population pharmacokinetic model and investigate the influence of these polymorphisms and other patient specific covariates on the pharmacokinetics of tenofovir. Results: The estimated glomerular filtration rate calculated by the Cockcroft and Gault equation, concomitant use of lopinavir/ritonavir and ABCC4 3463A>G polymorphism were associated with tenofovir apparent oral clearance (CL/F). The use of lopinavir/ritonavir decreased tenofovir CL/F by 25%. Patients carrying ABCC4 3463 AG or GG had a tenofovir CL/F 11% higher than those with genotype AA. Conclusion: Renal function, co-medication and genetic variation impact the pharmacokinetics of tenofovir. These factors should be taken into consideration to guide the individual tenofovir disoproxil fumarate dosage regimen in Thai HIV-infected patients.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyArticleSCOPUS10.2217/pgs-2017-0128